Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Jordan C. Pruce"'
1
Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases
Autor: Rahul S Dalal, Jordan C Pruce, Jessica R Allegretti
Publikováno v: Inflammatory Bowel Diseases. 29:830-833
Lay Summary In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both achieving and maintaining clinical remission for >40% of inflammatory bowel disease patients fo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d2c3f38d8a8a4557fcf9cbc1e3265a
https://doi.org/10.1093/ibd/izac164
Zobrazit plný text záznamu
2
1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure
Autor: Rahul S Dalal, Puza P Sharma, Kanwal Bains, Jordan C Pruce, Jessica R Allegretti
Publikováno v: Inflammatory Bowel Diseases.
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Real-world data comparing the effectiveness of tofacitinib to ustekinumab are limited. We compared 52-week outcomes of tofacitinib vs ustekinumab f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::653457de3400dc7b74ca5dce1ec7360f
https://doi.org/10.1093/ibd/izad087
Zobrazit plný text záznamu
3
P261 Predictors and outcomes of ustekinumab dose escalation to every 4 or every 6 weeks in ulcerative colitis: a multicenter cohort study in the United States
Autor: Rahul S. Dalal, Edward L. Barnes, Jessica R. Allegretti, Jenna Marcus, Scott Esckilsen, Jordan C. Pruce
Publikováno v: Journal of Crohn's and Colitis. 15:S296-S298
Background Patients with ulcerative colitis (UC) on ustekinumab (UST) therapy may have suboptimal response to standard every 8 week (q8w) dosing. Empiric dose escalation to q4w or q6w is common, but the efficacy of these strategies are unknown in UC.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4f2ac1e7a52d04e427bda74b4b9f353
https://doi.org/10.1093/ecco-jcc/jjab076.387
Zobrazit plný text záznamu
4
Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study
Autor: Jordan C. Pruce, Jessica R. Allegretti, Rahul S. Dalal, Jenna Marcus, Scott Esckilsen, Edward L. Barnes
Publikováno v: Clinical Gastroenterology and Hepatology. 20:2399-2401.e4
Ustekinumab has been shown to be effective for the treatment of ulcerative colitis (UC); however, >40% of patients have suboptimal clinical response after induction and maintenance dosing every 8 weeks.1,2 The best management approach for these patie
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87d04a3bf4af2bb6b2f35f0363cc0f03
https://doi.org/10.1016/j.cgh.2021.03.028
Zobrazit plný text záznamu
6
Cost-effectiveness analysis of sequential fecal microbiota transplantation for fulminant Clostridioides difficile infection
Autor: Jinyi Zhu, Sanchit Gupta, Zain Kassam, Colleen R. Kelly, Monika Fischer, Jessica R. Allegretti, Jordan C. Pruce, Thomas R. McCarty
Publikováno v: Journal of gastroenterology and hepatologyReferences. 36(9)
BACKGROUND AND AIM Fulminant Clostridioides difficile infections (FCDI) account for 8% of cases and substantial healthcare burden. Fecal microbiota transplantation is recommended for recurrent CDI, but emerging data support use for FCDI. We aimed to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ecd7681b115736767c12ea81bcfed57
https://pubmed.ncbi.nlm.nih.gov/33682170
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje